ModifiedCentenePolicy CP PMN.281

Topiramate Extended-Release (Qudexy XR, Trokendi XR)

This policy defines medical necessity criteria, dosing limits, and prior authorization requirements for Qudexy XR and Trokendi XR for members of Centene-affiliated health plans (Commercial, HIM, Medicaid) for seizure disorders and migraine prophylaxis.

Policy Summary

PayerCentene

PolicyTopiramate Extended-Release (Qudexy XR, Trokendi XR)

Policy CodePolicy CP PMN.281

Change TypeClarified and added generic redirection requirements

Effective DateSep 1, 2022

Next Review Date

Key ActionPrior authorization required with documentation and trials of generic immediate‑release (and when required, generic extended‑release) topiramate at up to maximally indicated doses.

SourceLink

POLICY UPDATE CHANGES

Revised 'Failure of a trial' language to template 'Member must use' language.

Extended the generic redirection requirement to the Continued Therapy section for seizures.

Clarified redirection language to require member must use generic extended-release topiramate (generic Qudexy XR) at up to maximally indicated doses unless contraindicated or adverse effects occur.

12 monthstypical approval duration (HIM/Medicaid)

12 monthstypical approval duration (Commercial)

400 mg/daymax dose (seizures)

100 mg/day

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

NVstate with step therapy limitation

Coverage Criteria

Initial Therapy (Seizures)

Covered when ALL of the following are met

Diagnosis of partial-onset seizures, primary generalized tonic-clonic seizures, OR Lennox-Gastaut syndrome

Age by product: For Qudexy XR: >= 2 years; For Trokendi XR: >= 6 years

Step therapy/setting: Either request is for treatment in a state with setting limitations (see Appendix D) OR both of the following are met: (i) trial of generic immediate-release topiramate at up to maximally indicated doses unless contraindicated or clinically significant adverse effects occurred; AND (ii) trial of generic extended-release topiramate (generic Qudexy XR) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects occurred

State-specific limitations referenced (see Appendix D)

Dose limits: Dose does not exceed indicated maxima by age and indication (see dosing tables)

See dosing appendices for age-specific maxima

Dosing Limits

Monotherapy (adults and pediatric >= 10 years): Maximum 400 mg per day<=400 mg/day

Applies to Qudexy XR and Trokendi XR per product dosing

Monotherapy (2 to 10 years): Age-based maximums as listed in policy (range 150 mg to 400 mg per day depending on age bracket)see policy table

Policy contains specific mg/day maxima by age bracket

Adjunctive therapy (>= 17 years): Maximum 400 mg per day<=400 mg/day

Migraine Prophylaxis Initial Therapy

Covered when ALL of the following are met

Age: Member is >= 12 years of age

Diagnosis of migraine headaches that require prophylaxis

Step therapy: Trial of generic immediate-release topiramate at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced; trial of generic extended-release topiramate (generic Qudexy XR) at up to maximally indicated doses when specified

Dose limit: Dose does not exceed 100 mg per day<=100 mg/day

Continued Therapy

Covered when ALL of the following are met

Current therapy: Member is currently receiving medication via Centene benefit or documentation supports member has received Qudexy XR or Trokendi XR for at least 30 days

Response: Member is responding positively to therapy

Documentation of clinical response required

Step therapy on renewal: Member must have used generic immediate-release topiramate (and generic extended-release when required) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced

Generic redirection requirement extended to continued therapy where applicable

Dose limits on renewal: If request is for a dose increase, the new dose must not exceed indication-specific maxima (including 100 mg/day for migraine prophylaxis)

Initial/Continued Therapy

Covered when ALL of the following are met

Redirection to generic formulations: Member must use generic extended-release topiramate (generic Qudexy XR) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects occur; member must use generic immediate-release topiramate at up to maximally indicated doses unless contraindicated or clinically significant adverse effects occur

Applies to initial and continued therapy; clarified language implemented in 3Q2024 and extended in 3Q2025

Dose increase limit: If request is for a dose increase, new dose must not exceed 100 mg per day when that ceiling is specified for the request<=100 mg/day for specified dose increase requests

Referenced in policy dosing constraints for certain requests

Indication and dosing within labeling: Dosing and maximums must align with product labeling: seizures up to 400 mg/day (age-dependent) and migraine prophylaxis up to 100 mg/day

Other diagnoses or indications not specifically covered in this policy are handled through the applicable formulary, non‑formulary, or no‑coverage policies for the member's line of business. Refer to the relevant policy documents (for example, CP.CPA.190, HIM.PA.33, CP PMN.255) when a requested use falls under formulary/no‑coverage pathways or has recent label changes not yet reflected in this policy.

Non‑FDA approved indications that are not addressed by this policy are excluded from coverage unless the provider submits sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policy for the member's line of business (for example, CP.CPA.09, HIM.PA.154, or CP.PMN.53).

Any use not listed among the authorized diagnoses and indications in this policy should be evaluated under the appropriate off‑label or non‑formulary policies for the applicable line of business. Providers should follow the referenced policies for submission and review requirements when seeking coverage for unlisted uses.

Requests for topiramate extended‑release to treat non‑FDA approved indications will be denied unless the request includes adequate supporting documentation consistent with the applicable off‑label use policy for the member's plan.

Coding and Dosage Summary

Policy identifiermixed

CP PMN.281

Reference/Policy number

Product availability / dosage formsmixed

NDC	Not specified in this document
Capsule strengths	25 mg, 50 mg, 100 mg, 200 mg (Trokendi XR)
Topiramate extended-release (generic Qudexy XR)	Available; dosing/maximums described (seizures up to 400 mg/day; migraine prophylaxis 100 mg/day)

Maximum dose for migraine prophylaxis — 100 mg per day

Maximum dose (migraine prophylaxis)100 mg per day

Age threshold (migraine prophylaxis)Indicated for members ≥12 years (policy criteria)

Step therapy requirementTrial of generic immediate-release topiramate at up to maximally indicated doses required prior to branded XR unless contraindicated or intolerant

Maximum adult monotherapy/adjunctive dose — 400 mg per day

Maximum adult monotherapy/adjunctive dose400 mg per day

Pediatric monotherapy guidanceMonotherapy for pediatric patients ≥10 years: up to 400 mg/day (age-based limits apply for younger ages)

Provider Actions and Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required. Provider must submit documentation (which may include office chart notes and laboratory results) supporting that the member has met all approval criteria. Failure to submit required documentation may result in denial of the request.

Prior authorization required with documentation of diagnosis, age‑appropriate indication, and trial of generic immediate‑release topiramate when applicable.
Provider must submit supporting documentation (office notes, labs) showing member has met all approval criteria and, for continuity of care requests, that member is currently responding to therapy.

Note

Approval Duration

Approvals will be issued for up to the durations shown below. For continuity of care or state‑mandated exceptions, refer to state addendums.

HIM/Medicaid: up to 12 months.
Commercial: up to 12 months or the duration of the request, whichever is less.

Background

Topiramate extended‑release products (Qudexy XR, Trokendi XR) are sulfamate‑substituted monosaccharide formulations indicated in labeling for seizure disorders (including partial‑onset seizures, primary generalized tonic‑clonic seizures, and Lennox‑Gastaut syndrome) and for migraine prophylaxis in specified age groups. This policy requires prior authorization and generally directs trials of generic immediate‑release topiramate — and generic extended‑release where specified — at up to maximally indicated doses prior to approval of branded extended‑release products. Dosing limits differ by indication: seizure indications follow age‑dependent maxima up to 400 mg/day, while migraine prophylaxis dosing is limited to 100 mg/day.

Definitions

Topiramate extended-release — definition (Qudexy XR, Trokendi XR)

DefinitionTopiramate extended-release is a sulfamate-substituted monosaccharide (examples: Qudexy XR, Trokendi XR)

Examples (brand names)Qudexy XR; Trokendi XR

Formulation classExtended-release topiramate formulations (XR)

Maximum dose per indication (seizures: up to 400 mg/day; migraine prophylaxis: 100 mg/day)

Maximum dose — seizuresUp to 400 mg/day (age-dependent maxima apply)

Maximum dose — migraine prophylaxis100 mg/day

Pediatric dosing note

Policy Summary

PayerCentene

PolicyTopiramate Extended-Release (Qudexy XR, Trokendi XR)

Policy CodePolicy CP PMN.281

Change TypeClarified and added generic redirection requirements

Effective DateSep 1, 2022

Next Review Date

Key ActionPrior authorization required with documentation and trials of generic immediate‑release (and when required, generic extended‑release) topiramate at up to maximally indicated doses.

SourceLink

On This Page

Adjunctive therapy (< 16 years):

9 mg/kg per day up to a maximum of 400 mg per day

9 mg/kg/day up to 400 mg

<= indication-specific maxima

See dosing tables for age- and indication-specific limits

400 mg/day or 100 mg/day depending on indication

See dosage and administration section and appendices

Coverage duration: Approvals are granted for up to 12 months for HIM/Medicaid; Commercial approvals up to 12 months or the duration of the request, whichever is less12 months

See authorization duration

Adjunctive pediatric dosingAdjunctive therapy: up to 9 mg/kg/day, not to exceed 400 mg/day

Maximum daily dose (seizures) — 400 mg/day

Maximum daily dose (seizures)400 mg/day

Age-dependent maximaPolicy lists lower maximums for specific younger age brackets; adults and older pediatric groups may reach 400 mg/day

Dose increase on renewalRequests for dose increases must not exceed indication-specific maxima (including 400 mg/day for seizures)

Maximum daily dose (migraine prophylaxis) — 100 mg/day

Maximum daily dose (migraine prophylaxis)100 mg/day

Dosing regimenTypical dosing range 25 to 100 mg PO once daily for migraine prophylaxis

Prior therapy requirementTrial of generic immediate-release (and generic extended‑release when specified) topiramate at maximally indicated doses required prior to branded XR

Documentation Required

Providers must submit clinical documentation demonstrating that the member has met the clinical criteria for initiation or continuation of therapy. Documentation should include evidence of prior trials when required, current response to therapy for continuation requests, and any relevant labs or office visit notes.

Supporting documentation may include office chart notes, medication history showing trial(s) of generic immediate‑release topiramate and/or generic extended‑release topiramate (generic Qudexy XR) at maximally indicated doses, and laboratory results as applicable.
For continuation requests, documentation must show the member is currently receiving and responding positively to Qudexy XR or Trokendi XR and has received the medication for at least 30 days, when applicable.
Failure to provide adequate documentation (e.g., no evidence of required prior trials or lack of clinical notes) may result in denial per policy.

Step Therapy

Step Therapy / Redirection Requirements

Step therapy/redirection requirements apply where specified: members must use generic immediate‑release topiramate (and where applicable generic extended‑release topiramate/generic Qudexy XR) at up to maximally indicated doses unless contraindicated or clinically significant adverse effects occur. Exceptions and state‑specific limitations (Appendix D) apply.

Member must use generic immediate‑release topiramate at up to maximally indicated doses prior to Qudexy XR or Trokendi XR, unless contraindicated or adverse effects are documented.
For Qudexy XR and Trokendi XR, member must use generic extended‑release topiramate (generic Qudexy XR) at up to maximally indicated doses when required, unless contraindicated or adverse effects documented.
State limits and continuity‑of‑care rules may override redirection/step therapy (see Appendix D and state addendums).

Pediatric adjunctive dosing: 5–9 mg/kg/day up to 400 mg/day; specific age brackets have lower maxima as listed in policy